Novartis, a Swiss-based drug manufacturer, has agreed to acquire AveXis, a US-based clinical stage gene therapy company.
It was reported on Monday that the deal is valued at USD8.7bn in an all-cash transaction. The deal has been unanimously approved by the boards of the two companies and Novartis will pay USD218 for each share of AveXis. It is intended to allow Novartis to grow its position in the gene therapy and neuroscience areas.
AveXis is currently carrying out several clinical studies for the treatment of spinal muscular atrophy (SMA). AveXis' lead gene therapy candidate is AVXS-101, which has been granted orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of SMA.
The acquisition is likely to be completed in the middle of this year, provided it successfully fulfils the tender offer and satisfies all other closing conditions.
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
FDA accepts Xspray Pharma's NDA for XS003 with PDUFA date set for June 2026
Citius Oncology and McKesson sign US distribution agreement for LYMPHIR
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Antengene reveals ATG-022 clinical data at ESMO 2025
WeightWatchers launches RxFlexFund to expand affordable GLP-1 access for employers and employees
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study